HMGCR and breast cancer: The prognostic impact of HMGCR in breast cancer has previously been evaluated by IHC in two independent cohorts; (1) a consecutive breast cancer cohort where patients with tumors expressing HMGCR had a significantly prolonged recurrence-free survival, also when adjusted for established prognostic factors15; and (2) a population-based cohort of primary breast cancer patients in Sweden, among whom HMGCR expression was not associated with disease-free survival16.